New markers to select children with cancer for trials with PARP inhibitors
Novel biomarkers for PARP inhibitor trials for children with cancer
We have been funding expert research since 2016, aiming to ensure that every child and young person has a safe and effective treatment for their cancer, and that they can live long and happy lives post-treatment.
Novel biomarkers for PARP inhibitor trials for children with cancer
What helps and what hinders in remotely delivered acceptance and commitment therapy for survivors of childhood brain tumours: a diary and interview study.
Understanding treatment decision-making processes in families where a child or young person has relapsed/refractory rhabdomyosarcoma
Identifying drivers of central nervous system involvement in T-cell acute lymphoblastic leukaemia
Drug repurposing targeting immunomodulatory Haem oxygenase-1 (HO-1) for prevention of osteosarcoma growth and metastasis
Evaluating the efficacy of Enhancer of Zeste Homolog 2 (EZH2) inhibitors in combination with anti-GD2/isotretinoin for the treatment of high-risk neuroblastoma: a pre-clinical study
The Role of Cut-and-Run, an Aberrant V(D)J Recombination Reaction, in the Development of Acute Lymphoblastic Leukaemias with Poor Prognosis
An open label, single centre, single arm, prospective feasibility study evaluating the effectiveness of near-infrared fluorescence(NIRF)using indo-cyanine green(ICG)in intra-abdominal or intra-thoracic minimally invasive surgery(MIS)in paediatric oncology.
MG-fnRMS and CINSARC gene expression signatures to predict relapse in fusion gene negative rhabdomyosarcomas: assessing an approach to improve patient outcomes